BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 27288062)

  • 41. Recent advances in the management of haemophilia and christmas disease.
    Biggs R
    Clin Haematol; 1979 Feb; 8(1):95-114. PubMed ID: 367667
    [No Abstract]   [Full Text] [Related]  

  • 42. Looking to the future of gene therapy for hemophilia A and B.
    Kaczmarek R; Herzog RW
    Expert Rev Hematol; 2023; 16(11):807-809. PubMed ID: 37798911
    [No Abstract]   [Full Text] [Related]  

  • 43. Factor concentrate prophylaxis for neonates with hemophilia.
    Buchanan GR
    J Pediatr Hematol Oncol; 1999; 21(4):254-6. PubMed ID: 10445886
    [No Abstract]   [Full Text] [Related]  

  • 44. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing.
    Mancuso ME; Mahlangu JN; Pipe SW
    Lancet; 2021 Feb; 397(10274):630-640. PubMed ID: 33460559
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The management of fractures in haemophilia and Christmas disease.
    Kemp HS; Matthews JM
    J Bone Joint Surg Br; 1968 May; 50(2):351-8. PubMed ID: 5651343
    [No Abstract]   [Full Text] [Related]  

  • 46. Pioneering designs for recombinant coagulation factors.
    Schulte S
    Thromb Res; 2011; 128 Suppl 1():S9-12. PubMed ID: 22221848
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A chamber of hope for hemophilia.
    Pipe SW; Kaufman RJ
    Nat Biotechnol; 2000 Mar; 18(3):264-5. PubMed ID: 10700134
    [No Abstract]   [Full Text] [Related]  

  • 48. [Hemophilia and HTLV-III infection].
    Lechler E
    Z Hautkr; 1986 Dec; 61(23):1687-704. PubMed ID: 2949442
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The promise and challenges of bioengineered recombinant clotting factors.
    Pipe SW
    J Thromb Haemost; 2005 Aug; 3(8):1692-701. PubMed ID: 16102035
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Treatment of hemophiliacs with inhibitors].
    Fujimaki M
    Rinsho Ketsueki; 1985 Jul; 26(7):1059-68. PubMed ID: 3932719
    [No Abstract]   [Full Text] [Related]  

  • 51. Therapy for AHF and PTC hemophilia. I.
    Seeler RA
    IMJ Ill Med J; 1970 May; 137(5):518-21. PubMed ID: 4392774
    [No Abstract]   [Full Text] [Related]  

  • 52. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.
    Schimpf K; Schwarz P; Kunschak M
    Thromb Haemost; 1995 Mar; 73(3):553-5. PubMed ID: 7667845
    [No Abstract]   [Full Text] [Related]  

  • 53. The management of musculoskeletal problems in hemophilia. Part I. Principles of medical management of hemophilia.
    McMillan CW; Greene WB; Blatt PM; White GC; Roberts HR
    Instr Course Lect; 1983; 32():210-6. PubMed ID: 6443730
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Concentrated antihemophilic globulin in the treatment of hemorrhagic syndromes].
    Baklaja F; Cvetković V; Stajić M; Krivokapić L
    Bilt Hematol Transfuz; 1976; 4(3):61-6. PubMed ID: 1008799
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Congenital deficiency of plasma thromboplastin component (PTC-factor IX): report of 25 cases from 19 unrelated families.
    Agarwal MB; Mehta BC
    J Assoc Physicians India; 1982 Jan; 30(1):17-9. PubMed ID: 6820363
    [No Abstract]   [Full Text] [Related]  

  • 56. Challenges for new haemophilia products from a manufacturer's perspective.
    Schulte S
    Thromb Res; 2014 Nov; 134 Suppl 1():S72-6. PubMed ID: 24360931
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Switching haemophilia products and inhibitor risk: a United States' perspective.
    Nance D; Rodgers GM
    Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
    [No Abstract]   [Full Text] [Related]  

  • 58. The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies.
    Engelfriet CP; Reesink HW; Mannucci PM; Gringeri A; Ingerslev J; Brettler DB; Mauser-Bunschoten EP; Negrier C; Berntorp E; Smith OP; Shapiro AD
    Vox Sang; 2000; 78(4):256-61. PubMed ID: 10970234
    [No Abstract]   [Full Text] [Related]  

  • 59. Prevention of bleeding in hemophilia patients with high-titer inhibitors.
    Leissinger CA; Konkle BA; Antunes SV
    Expert Rev Hematol; 2015 Jun; 8(3):375-82. PubMed ID: 25937074
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Haemophilia treatment in the United Kingdom from 1969 to 1974.
    Biggs R
    Br J Haematol; 1977 Apr; 35(4):487-504. PubMed ID: 871406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.